Other Cancer News
Top Stories
Vaginal Bleeding After Menopause Could Be A Sign Of Cancer
POSTED: May 6, 2008Women who experience unexpected vaginal bleeding after menopause should always consult their gynecologist, said Germany's professional association for gynecologists. Vaginal bleeding after menopause could indicate cancer of the uterus, according to the Munich-based association. Women not yet in menopause who experience unusually heavy or i...
Study Discovers How Moles Become Cancerous
POSTED: May 6, 2008STATE COLLEGE, Pa. -- U.S. scientists say they've discovered how a mole develops into melanoma by showing the interaction of two proteins involved in up to 70 percent of tumors. "We have shown that when two proteins (B-Raf and Akt3) communicate with one another in a mole, they cooperate, leading to the development of melanoma," said Penn Stat...
Genetic Map Of A Cancerous Bladder Created
POSTED: May 6, 2008HOUSTON -- U.S.-led cancer researchers have created a physical-genetic map depicting a cancerous bladder's molecular journey from normal cells to malignancy. Scientists at The University of Texas M.D. Anderson Cancer Center said by geographically relating an organ's varied tissues to their underlying genetic variation or regulation, the team ...
Particular Experimental Therapy Not More Effective Than Standard Treatment For Anal Canal Cancer
POSTED: May 2, 2008Use of chemotherapy with the drug cisplatin before other treatments did not improve disease-free survival for patients with anal canal cancer compared to the standard treatment regimen, and resulted in a higher rate of colostomy procedures, according to a study in the April 23/30 issue of JAMA. Chemoradiation is the preferred primary therapy for pati...
New Genetic Techniques To Combat Lung Cancer
POSTED: May 2, 2008New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland. In one report (Abstract No. 81O; Friday ...
Mutation Database Helps Personalized Treatment Of Lung Cancer
POSTED: May 2, 2008A groundbreaking free tool to help oncologists choose the best therapies for patients with non-small-cell lung cancer has been launched this week by scientists at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, ...
Analysis Shows Combining Sorafenib With Carboplatin/paclitaxel Adds No Benefit In Lung Cancer
POSTED: May 2, 2008A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival. In a ...
Viruses May Play A Role In Lung Cancer Development
POSTED: May 2, 2008Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer. Experts agree that smoking is...
New Ovarian Cancer Quality Of Care Study Findings Have Been Reported By Scientists At National Cancer Institute
POSTED: May 2, 2008A report, 'A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a gynecologic oncology group study,' is newly published data in Cancer Epidemiology, Biomarkers & Prevention. According to a study from the United States, "W...
Proteolix Initiates Phase 2 Clinical Trial Of Carfilzomib In Patients With Relapsed Solid Tumors
POSTED: May 2, 2008SOUTH SAN FRANCISCO, Calif. -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 2 clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in relapsed solid tumors. A Phase 1b dose-escalation trial of carfilzomib in patients with advanced solid tumors has recently been completed. The Phas...
